Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort
Standard
Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. / Funke-Kaiser, Anne; Havulinna, Aki S.; Zeller, Tanja; Appelbaum, Sebastian; Jousilahti, Pekka; Vartiainen, Erkki; Blankenberg, Stefan; Sydow, Karsten; Salomaa, Veikko.
In: ANN MED, Vol. 46, No. 3, 05.2014, p. 155-162.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort
AU - Funke-Kaiser, Anne
AU - Havulinna, Aki S.
AU - Zeller, Tanja
AU - Appelbaum, Sebastian
AU - Jousilahti, Pekka
AU - Vartiainen, Erkki
AU - Blankenberg, Stefan
AU - Sydow, Karsten
AU - Salomaa, Veikko
N1 - Funding Information: Declaration of interest: T his work has been sustained by the MORGAM Project’s current funding: European Community FP 7 projects ENGAGE CHANCES and BiomarCaRE. V.S. was supported by the Finnish Foundation for Cardiovascular Research. S.B. has received research funding from Abbott, Abbott Diagnostics, Bayer, Boehringer Ingelheim, SIEMENS, and Thermo Fisher. He received honoraria for lectures from Abbott, Abbott Diagnostics, Astra Zeneca, Bayer, Boehringer Ingelheim, Medtronic, Pfizer, Roche, SIEMENS Diagnostics, SIEMENS, Thermo Fisher, and as member of Advisory Boards and for consulting for Boehringer Ingelheim, Bayer, Novartis, Roche, and Thermo Fisher. All other authors did not report any conflict.
PY - 2014/5
Y1 - 2014/5
N2 - Introduction. To examine whether midregional pro-adrenomedullin (MR-proADM) plasma concentrations predict incident cardiovascular outcomes in the general population. Natriuretic peptides (N-terminal pro-brain natriuretic peptide (NT-proBNP), B-type natriuretic peptide (BNP), and midregional pro-atrial natriuretic peptide (MR-proANP)) were analyzed for comparison. Material and methods. MR-proADM plasma concentrations and those of the natriuretic peptides were determined in 8444 individuals of the FINRISK 1997 cohort. Patients were followed for 14 years (median). Cox regression analyses, discrimination, and reclassification analyses adjusting for Framingham risk factors were performed to evaluate the additional benefit from MR-proADM. Results. MR-proADM concentrations significantly predicted all-cause death (hazard ratio highest quintile versus lowest 1.18, 95% confidence interval 1.08-1.28), stroke (1.20, 1.05-1.38), major adverse cardiac events (MACE) (1.27, 1.17-1.37), and heart failure (1.67, 1.49-1.87). MR-proADM remained associated with MACE, death, and heart failure even after additional adjustment for NT-proBNP and C-reactive protein. Adding MR-proADM to the Framingham risk factors significantly improved discrimination (P < 0.001 for C-statistics and integrated discrimination improvement) and risk reclassification for heart failure (net reclassification improvement 12.12%, P < 0.001). Conclusions. In a healthy general population sample of the FINRISK 1997 cohort MR-proADM significantly predicted all-cause death, MACE, and especially heart failure even beyond NT-proBNP. It also improved risk reclassification for heart failure.
AB - Introduction. To examine whether midregional pro-adrenomedullin (MR-proADM) plasma concentrations predict incident cardiovascular outcomes in the general population. Natriuretic peptides (N-terminal pro-brain natriuretic peptide (NT-proBNP), B-type natriuretic peptide (BNP), and midregional pro-atrial natriuretic peptide (MR-proANP)) were analyzed for comparison. Material and methods. MR-proADM plasma concentrations and those of the natriuretic peptides were determined in 8444 individuals of the FINRISK 1997 cohort. Patients were followed for 14 years (median). Cox regression analyses, discrimination, and reclassification analyses adjusting for Framingham risk factors were performed to evaluate the additional benefit from MR-proADM. Results. MR-proADM concentrations significantly predicted all-cause death (hazard ratio highest quintile versus lowest 1.18, 95% confidence interval 1.08-1.28), stroke (1.20, 1.05-1.38), major adverse cardiac events (MACE) (1.27, 1.17-1.37), and heart failure (1.67, 1.49-1.87). MR-proADM remained associated with MACE, death, and heart failure even after additional adjustment for NT-proBNP and C-reactive protein. Adding MR-proADM to the Framingham risk factors significantly improved discrimination (P < 0.001 for C-statistics and integrated discrimination improvement) and risk reclassification for heart failure (net reclassification improvement 12.12%, P < 0.001). Conclusions. In a healthy general population sample of the FINRISK 1997 cohort MR-proADM significantly predicted all-cause death, MACE, and especially heart failure even beyond NT-proBNP. It also improved risk reclassification for heart failure.
KW - BiomarCaRE
KW - Biomarkers
KW - Cardiovascular disease
KW - Heart failure
KW - Midregional pro-adrenomedullin
KW - Natriuretic peptides
KW - Risk factor
UR - http://www.scopus.com/inward/record.url?scp=84899798859&partnerID=8YFLogxK
U2 - 10.3109/07853890.2013.874662
DO - 10.3109/07853890.2013.874662
M3 - SCORING: Journal article
C2 - 24506434
AN - SCOPUS:84899798859
VL - 46
SP - 155
EP - 162
JO - ANN MED
JF - ANN MED
SN - 0785-3890
IS - 3
ER -
